CHARLOTTE, N.C., Feb. 10 /CNW/ -- USHIFU, a worldwide leader in the
development, distribution and use of minimally invasive high intensity focused
ultrasound technologies, is pleased to announce the appointment of Mark
Schoenberg, M.D. to the consulting position of Chief Medical Officer. Dr.
Schoenberg is an internationally recognized expert in the area of Urologic
Oncology who has authored more than 100 peer-reviewed publications and has 15
years experience as a clinical investigator.
Dr. Schoenberg will assist the company in its current effort to complete
critical clinical trials with the Sonablate(R) 500 technology in the treatment
of patients with prostate cancer. Additionally, he will spearhead a scholarly
effort to critically evaluate current clinical experiences with HIFU therapy
in collaboration with the Sonablate(R) International HIFU Registry.
Dr. Schoenberg will help USHIFU create educational materials describing
the use of HIFU technology and will assist in developing a series of
initiatives for the treatment of other malignancies. Dr. Schoenberg has an
active clinical practice and serves as a Professor of Urology at Johns Hopkins
Steve Puckett, Jr., USHIFU CEO said, "We are thrilled to announce the
addition of Dr. Mark Schoenberg to the USHIFU team as Chief Medical Officer of
our company. I've had the privilege of working with Dr. Schoenberg on a
consulting basis over the past several months and his contributions towards
our clinical trial research and academic relationships have been extremely
valuable. We look forward to leveraging Dr. Schoenberg's unique skill set as
we continue to build a world class healthcare organization."
About USHIFU, LLC
USHIFU, based in Charlotte, NC, is a worldwide leader in the development,
distribution and use of minimally invasive high intensity focused ultrasound
technologies. Dr. Schoenberg holds no equity in USHIFU.
About the Sonablate(R) 500
The Sonablate(R) 500 is a minimally invasive medical device that utilizes
ultrasound energy to destroy tissue within the body. It was developed by FSI
and is manufactured by Misonix, Inc. (Nasdaq: MSON) who also holds
distribution rights in Europe. Takai Hospital Supply Ltd. and THS
International distribute the Sonablate(R) 500 in Southeast Asia and the Middle
The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R)
500 remains investigational in the U.S. and is being studied for the treatment
of prostate cancer in clinical trials in the U.S. FDA has made no decision as
to the safety or efficacy of the Sonablate(R) 500 for the treatment of
For further information:
For further information: Amanda Willis of USHIFU, +1-704-936-1823,
email@example.com Web Site: http://www.internationalhifu.com